Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzyl Phenethylcarbamate SCHEMBL4287199 | 0.91 | LMNA (0.73) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL10305302 | 0.88 | LMNA (0.61) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL6554125 | 0.88 | LMNA (0.65) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| Benzyl Phenethylcarbamate SCHEMBL6392045 | 0.86 | LMNA (0.67) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL160715 | 0.85 | LMNA (0.61) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL2851561 | 0.85 | LMNA (0.61) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL13884390 | 0.85 | LMNA (0.61) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL8802503 | 0.85 | LMNA (0.61) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL23291312 | 0.84 | MAPT (0.66) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL6748819 | 0.83 | HTT (0.72) | LMNASMN1; SMN2HTTL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1876179-B1 | Thienopyrimidone compounds | TAKEDA PHARMACEUTICAL (JP) | 2015-03-25 | — | — | EP | disclosed |
| US-7989445-B2 | Thienopyrimidone compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7989445-B2 | Thienopyrimidone compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-20100069362-A1 | Thienopyrimidone compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069362-A1 | Thienopyrimidone compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-1876179-A1 | THIENOPYRIMIDONE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-5250426-A | Catalytic hydrolysis using monoclonal antibodies | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069362-A1 | Thienopyrimidone compound | MC1R, MC2R, MC5R | LMNA 4733/4885SMN1; SMN2 3933/4885HTT 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.